All In Biotech

Drug Trial Radar · NCT06698250

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Phase II Trial of Zanzalintinib (XL-092) in Combination With Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 18, 2024

Primary completion

Dec 31, 2026

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Anwaar SaeedAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Exelixis
First posted
Nov 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).

Conditions

  • Hepatocellular Carcinoma

Interventions

  • ZanzalintinibDrug

    Next generation tyrosine kinase inhibitor (TKI) with the target inhibition profile identical to cabozantinib but with a superior pharmacokinetic profile.

  • DurvalumabDrug

    Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279)

  • TremelimumabDrug

    Tremelimumab is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma designed to attach to and block CTLA-4, a protein that controls the activity of T cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended phase 2 dose (RP2D) of XL-092 with Durvalumab plus TremelimumabTime frame: Up to 12 months
  2. Objective Response Rate (ORR) (im RECIST)Time frame: Up to 24 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Mays Cancer Center, UT Health San Antonio

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.